TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07285460: A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Sponsor: Sanofi · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 85 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,631,010

Rescue Site Savings

+$3,729,630

Unlock Full NCT07285460 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07285460 Rescue Dossier →